Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-1116 in Sjögren's Syndrome
NCT06312020Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of VIB-1116 in Sjogren's syndrome (8 arms), sponsored by Amgen. Primary endpoints: European Alliance of Associations for Rheumatology Sjogren's Syndrome Disease Activity Index at 48 weeks and EULAR Sjogren's Syndrome Patient Reported Index at 24 weeks. Started May 2024; status: terminated.
02
Drugs
VIB-1116
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT06312020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312020.